Stock Track | ARS Pharmaceuticals (SPRY) Surges 5.18% Pre-market on Raymond James' Target Price Hike

Stock Track03-24

ARS Pharmaceuticals Inc (SPRY) saw its stock soar 5.18% in pre-market trading on Monday, as investors reacted positively to a significant target price increase from a major financial institution.

Raymond James, a well-respected investment bank and financial services company, raised its target price for ARS Pharmaceuticals from $28 to $32. This represents a substantial 14.3% increase in the firm's valuation of the pharmaceutical company's stock.

The target price hike suggests that Raymond James analysts have become more optimistic about ARS Pharmaceuticals' future prospects. This could be due to various factors such as promising drug pipeline developments, improved financial performance, or positive industry trends. The increased target price may encourage more investors to consider SPRY stock, potentially driving further gains in the coming trading sessions.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1168497902?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-24 20:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168497902","market":"us","top_or_hot":-1,"title":"Stock Track | ARS Pharmaceuticals (SPRY) Surges 5.18% Pre-market on Raymond James' Target Price Hike","media":"Stock Track","content":"<p>ARS Pharmaceuticals Inc (SPRY) saw its stock soar 5.18% in pre-market trading on Monday, as investors reacted positively to a significant target price increase from a major financial institution.</p>\n\n<p>Raymond James, a well-respected investment bank and financial services company, raised its target price for ARS Pharmaceuticals from $28 to $32. This represents a substantial 14.3% increase in the firm's valuation of the pharmaceutical company's stock.</p>\n\n<p>The target price hike suggests that Raymond James analysts have become more optimistic about ARS Pharmaceuticals' future prospects. This could be due to various factors such as promising drug pipeline developments, improved financial performance, or positive industry trends. The increased target price may encourage more investors to consider SPRY stock, potentially driving further gains in the coming trading sessions.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ARS Pharmaceuticals (SPRY) Surges 5.18% Pre-market on Raymond James' Target Price Hike</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ARS Pharmaceuticals (SPRY) Surges 5.18% Pre-market on Raymond James' Target Price Hike\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-03-24 20:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ARS Pharmaceuticals Inc (SPRY) saw its stock soar 5.18% in pre-market trading on Monday, as investors reacted positively to a significant target price increase from a major financial institution.</p>\n\n<p>Raymond James, a well-respected investment bank and financial services company, raised its target price for ARS Pharmaceuticals from $28 to $32. This represents a substantial 14.3% increase in the firm's valuation of the pharmaceutical company's stock.</p>\n\n<p>The target price hike suggests that Raymond James analysts have become more optimistic about ARS Pharmaceuticals' future prospects. This could be due to various factors such as promising drug pipeline developments, improved financial performance, or positive industry trends. The increased target price may encourage more investors to consider SPRY stock, potentially driving further gains in the coming trading sessions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"","article_id":"1168497902","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168497902","pubTimestamp":1742818218,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"ARS Pharmaceuticals Inc  saw its stock soar 5.18% in pre-market trading on Monday, as investors reacted positively to a significant target price increase from a major financial institution.Raymond James, a well-respected investment bank and financial services company, raised its target price for ARS Pharmaceuticals from $28 to $32. This represents a substantial 14.3% increase in the firm's valuation of the pharmaceutical company's stock.The target price hike suggests that Raymond James analysts ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"由于Raymond James上调目标价，ARS Pharmaceuticals(SPRY)盘前飙升5.18%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPRY":1},"content_text":"ARS Pharmaceuticals Inc (SPRY) saw its stock soar 5.18% in pre-market trading on Monday, as investors reacted positively to a significant target price increase from a major financial institution.\nRaymond James, a well-respected investment bank and financial services company, raised its target price for ARS Pharmaceuticals from $28 to $32. This represents a substantial 14.3% increase in the firm's valuation of the pharmaceutical company's stock.\nThe target price hike suggests that Raymond James analysts have become more optimistic about ARS Pharmaceuticals' future prospects. This could be due to various factors such as promising drug pipeline developments, improved financial performance, or positive industry trends. The increased target price may encourage more investors to consider SPRY stock, potentially driving further gains in the coming trading sessions.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1168497902"}